GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » Price-to-Free-Cash-Flow

Matinas BioPharma Holdings (Matinas BioPharma Holdings) Price-to-Free-Cash-Flow : N/A (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings Price-to-Free-Cash-Flow?

As of today (2024-05-22), Matinas BioPharma Holdings's share price is $0.1699. Matinas BioPharma Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.08. Hence, Matinas BioPharma Holdings's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Matinas BioPharma Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

MTNB's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 33.09
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Matinas BioPharma Holdings's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.08.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 6.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.30% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.40% per year.

During the past 11 years, Matinas BioPharma Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 18.90% per year. The lowest was -3.40% per year. And the median was 8.50% per year.


Matinas BioPharma Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Matinas BioPharma Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Price-to-Free-Cash-Flow Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Matinas BioPharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Matinas BioPharma Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Matinas BioPharma Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Price-to-Free-Cash-Flow falls into.



Matinas BioPharma Holdings Price-to-Free-Cash-Flow Calculation

Matinas BioPharma Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.1699/-0.078
=N/A

Matinas BioPharma Holdings's Share Price of today is $0.1699.
Matinas BioPharma Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Matinas BioPharma Holdings  (AMEX:MTNB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Matinas BioPharma Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Executives
Liu Hui officer: Chief Technology Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921